Meta AnalysisID 3878
孕烯醇酮辅助治疗精神分裂症：随机对照试验的Meta分析
CRD42021233396
The aim of this study was to conduct a meta-analysis of the efficacy and safety of adjunctive pregnenolone for schizophrenia. Clinical efficacy indicators (PANSS) were used to determine whether the mental symptoms of sc
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 3878
- Evidence Id
- 12436
- Core Evidence Id
- 12436
- Source Meta Analysis Id
- 3835
- Herb2 Meta Analysis Id
- HBMA003835
- Crd Id
- CRD42021233396
- Title
- Adjunctive pregnenolone for schizophrenia: a meta-analysis of randomized controlled trials
- Review Question
- The aim of this study was to conduct a meta-analysis of the efficacy and safety of adjunctive pregnenolone for schizophrenia. Clinical efficacy indicators (PANSS) were used to determine whether the mental symptoms of schizophrenia patients improved, so as to infer whether pregnenolone is an effective, safe and reasonable choice for adjuvant treatment of schizophrenia.
- Study Type Included
- Study design: all RCTS were publicly published.
- Condition Being Studied
- As a chronic psychiatric disorder, schizophrenia affects the worldwide population with a lifetime prevalence of 1% and considerable long-term morbidity, mortality, and burden. Patients with schizophrenia often have positive or negative symptoms. Routine treatment regimens are accompanied by adverse effects, and a significant portion of patients remain symptomatic despite treatment, especially those with negative symptoms, which are frequently severe and strongly correlated with decreased functional outcome and quality of life. Despite the large number of psychotropic medications currently available, effective management of schizophrenia continues to be a challenging task. New treatment strategies are therefore necessary to address these important dimensions of schizophrenia symptomatology.
- Participant
- Participants: patients that suffer from schizophrenia, chronic schizophrenia or schizoaffective disorder.
- Animal
- Human Disease Modelled
- Intervention
- Intervention: study group given pregnenolone.
- Comparator Control
- Comparison: control group were given placebo.
- Main Outcome
- The main outcome is the negative symptoms of schizophrenia. Measures of effect The primary rating instrument are PANSS negative subscal scores and SANS score.
- Outcome Measure
- Additional Outcome
- The additional outcomes include the severity of psychiatric symptoms, function, the positive symptoms and general psychopathological symptoms of schizophrenia. Measures of effect The rating instruments are the PANSS positive subscal scores, the PANSS total score, the PANSS general score, and the GAF score.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Humans; Mental Disorders; Mental Health; Pregnenolone; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome
- Contact
- Mengrong Xu [email protected]
- Organisational Affiliation
- Shandong Mental Health Center; Cheeloo College of Medicine, Shandong University
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-01-26
- Registration Date
- 2021-02-01
- Anticipated Start Date
- 2020-12-25
- Anticipated Completion Date
- 2021-07-27
- Title Cn
- 孕烯醇酮辅助治疗精神分裂症：随机对照试验的Meta分析
- Title En
- Adjunctive pregnenolone for schizophrenia: a meta-analysis of randomized controlled trials
- Bilingual Status
- complete